Covid19 Members

LATEST

Media Inquiries

United States

Carolyn Posner

Phone: +1 202-281-7345

Email: cposner@usibc.com


India

Priyanka Sethi

Phone: +91 9899487687

Email: psethi@usibc.com


Membership

Ryan Miller

Phone: +1 202-725-8257

Email: rmiller@usibc.com


Michael Ridings

Phone: +1 202-463-3132

Email: mridings@usibc.com


Gilead Sciences

Gilead has worked with speed, care and diligence to prepare for the possibility that the company’s investigational antiviral remdesivir may be found effective against the virus that causes COVID-19. Recent clinical trial results and the decision by the U.S. Food & Drug Administration to issue an Emergency Use Authorization for remdesivir have highlighted the urgency of this work and the importance of planning for access to remdesivir globally.

Gilead’s overarching goal is to make remdesivir both accessible and affordable to governments and patients around the world, where authorized by regulatory authorities.  Given the urgent needs of patients globally, the company is in discussions with some of the world’s leading chemical and pharmaceutical manufacturing companies about their ability, under voluntary licenses, to produce remdesivir for Europe, Asia and the developing world through at least 2022.